FLT3 and acute myeloid leukemia: Due to the outstanding preclinical outcomes, Crenolanib entered clinical trials to elucidate its safety and tolerability with standard traditional chemotherapy in patients with mutated FLT3 AML cells (NCT02283177) [110].